Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Two Proteins Critical for Circadian Cycles Protect Cells from Mutations

By LabMedica International staff writers
Posted on 17 Mar 2015
Scientists have discovered that two proteins critical for maintaining healthy day-night cycles also have an unexpected role in DNA repair and protecting cells against genetic mutations that could lead to cancer and other diseases.

The new study was carried out by researchers from The Scripps Research Institute (TSRI; La Jolla, CA, USA). More...
“These proteins play an important role in the response to DNA damage,” said senior author Katja Lamia, “Researchers might eventually harness that knowledge for pharmaceutical targeting.”

People with unusual sleep schedules, such as flight attendants or rotating night-shift nurses, are at higher risk for certain health problems. The human body senses light and adjusts rhythms to the day-night cycle via the circadian clock. Hunger and sleepiness, for example, are strongly influenced by this clock. “When you have a deregulation of your circadian clock, you’re more prone to develop some kind of pathology, like diabetes, cancer, or heart disease,” said co-first author and research associate Anne-Laure Huber.

To investigated a possible cause of these health disparities, the team focused on the role of the circadian transcriptional repressors cryptochrome 1 (Cry1) and 2 (Cry2), which evolved from bacterial light-activated DNA repair enzymes. While cryptochromes are no longer light-activated, they do hold to a daily-regulated schedule, and stability of Cry1 and Cry2 is critical for circadian clock function. In humans, cryptochromes are essential for regulating blood sugar levels and protein production on a day-night cycle, but no longer have a direct role in DNA repair activity.

The study was initiated with proteomic screening to fish out proteins that could bind Cry1 or Cry2. The team found that Cry1 could bind Hausp, which has a known role in regulating the anti-cancer protein p53. The screening also showed that Hausp binds Cry2, but less strongly, suggesting that the nearly identical Cry1 and Cry2 have different roles related to DNA repair. “Most of the time people study them as redundant proteins, but we show that they have distinct functions in this DNA-repair pathway,” said Dr. Lamia.

Genetic expression experiments then showed that Hausp stabilizes Cry1, which helps prevent potential errors in DNA transcription that could occur upon DNA exposure to radiation. “This is very cool,” said co-first author and graduate student Stephanie Papp, “These proteins can sense that something is wrong in the cells.” When the researchers blocked Cry2 production, the cells no longer activated p21, a protein that stops mutant cells from dividing. “This could suggest that cells without Cry2 would be more susceptible to cancer,” said Dr. Lamia.

These and additional findings of the study showed that while Cry1/2 no longer directly repair DNA, they have adapted to provide an indirect role in the repair process, protecting genomic integrity via coordinated transcriptional regulation. This new link between circadian clock proteins and DNA repair is a clue to how disrupting day-night cycles could harm health.

The study, by Papp SJ, Huber AL, et al, was published March 10, 2015, in the journal eLife.

Related Links:

The Scripps Research Institute



Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Verification Panels for Assay Development & QC
Seroconversion Panels
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
Blood Glucose Reference Analyzer
Nova Primary
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.